Methods: We retrospectively (May 2020–August 2022) reviewed patients ≥ 18 years of age who received Tenecteplase (TNK) or tissue plasminogen activator (tPA) for AIS at our stroke center. The gene discussed is PLAT; the disease is stroke disorder.